Alembic Pharmaceuticals moves up receiving USFDA tentative approval for Febuxostat Tablets

07 Jul 2016 Evaluate

Alembic Pharmaceuticals is currently trading at Rs 581.95, up by 4.95 points or 0.86% from its previous closing of Rs. 577.00 on the BSE.

The scrip opened at Rs. 588.00 and has touched a high and low of Rs 590.00 and Rs 580.30 respectively. So far 5858 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs 791.70 on 15-Jul-2015 and a 52 week low of Rs. 514.35 on 05-Feb-2016.

Last one week high and low of the scrip stood at Rs 590.00 and Rs 545.45 respectively. The current market cap of the company is Rs. 10959.37 crore.

The promoters holding in the company stood at 74.13%, while Institutions and Non-Institutions held 12.92% and 12.96% respectively.

Alembic Pharmaceuticals has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Febuxostat Tablets, 40 mg and 80 mg. Febuxostat Tablets are indicated for the chronic management of hyperuricemia in patients with gout.

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Uloric Tablets, 40 mg and 80 mg of Takeda Pharmaceuticals USA, Inc. According to IMS, Uloric had an estimated market size of $430 million for twelve months ending December 2015.

Besides, Alembic has settled the case with Takeda and will launch its generic as per the terms of the settlement. The pharma major now has a total of 48 ANDA approvals (43 Final approvals and 5 tentative approvals) from USFDA.

Alembic Pharma Share Price

1035.30 -19.70 (-1.87%)
23-Dec-2024 09:49 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1798.00
Dr. Reddys Lab 1338.95
Cipla 1467.15
Lupin 2132.75
Zydus Lifesciences 964.70
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.